A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
NCT02157103
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
DRUG:
Bevacizumab 25 mg in 1 ml subcutaneously daily
Sponsor
Emory University